Protein / target
3-oxo-5-alpha-steroid 4-dehydrogenase 1
Protein at a glance
Biological role
3-oxo-5-alpha-steroid 4-dehydrogenase (NADP+) activity
Primary system
Endocrine & metabolic
Strongest disease association
hypertrophic cardiomyopathy
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Catalyzes the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms (PubMed:2339109, PubMed:23685396). Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development (PubMed:2339109, PubMed:23685396). Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles (PubMed:2339109). Hence, it plays a central role in sexual differentiation and androgen physiology (PubMed:2339109)
Subcellular location
Domains and Gene Ontology detail (43)Hide
Gene Ontology
- Ccell body fiber
- Cendoplasmic reticulum membrane
- Cneuronal cell body
- Cperinuclear region of cytoplasm
- F3-oxo-5-alpha-steroid 4-dehydrogenase (NADP+) activity
- F3-oxo-5-alpha-steroid 4-dehydrogenase activity
- Famide binding
- Felectron transfer activity
- FNADPH binding
- Pandrogen biosynthetic process
- Pandrogen catabolic process
- Pbone development
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·3-oxo-5-alpha-steroid 4-dehydrogenase (NADP+) activity
- ·3-oxo-5-alpha-steroid 4-dehydrogenase activity
- ·diterpenoid metabolic process
- ·progesterone metabolic process
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Steroid 5-alpha-reductase inhibitor
Appears in clinical studies involving prostate cancer, prostate neoplasm, neoplasm, cancer
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 164 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 2 total
androgenetic alopecia · prostate carcinoma · benign prostatic hyperplasia
prostate cancer · prostate neoplasm · neoplasm
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- New publicationAR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.
- New publicationLuteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.
- New publicationCirculating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.
- New publicationRucaparib or Physician's Choice in Metastatic Prostate Cancer.
- Regulatory approval
Approval: Abiraterone Mylan (EMA)
- Regulatory approval
Approval: Abiraterone Krka (EMA)
- Regulatory approval
Approval: Abiraterone Accord (EMA)
- New publicationOlaparib for Metastatic Castration-Resistant Prostate Cancer.
- New publicationCabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
- New publicationGenomic correlates of clinical outcome in advanced prostate cancer.
- New publicationAddition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Accelerated approval granted
Accelerated approval: Zytiga (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.